DRUG INTERACTIONS

Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability. Aachen, Germany, 2 June 2025 – Grünenthal today announced the acquisition of the commercial rights to Cialis® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company.

Over the next few years, Grünenthal and Lilly will work together to transfer the manufacturing to Grünenthal's production site in Santiago, Chile, that will supply Cialis® for Mexico, Brazil and Colombia moving forward.

16.1 How Supplied

Archived from the original on 13 November 2014. "The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. Archived from the original on 16 December 2017. "Drugs giant says its new pill will pack more punch than rival Viagra". Archived from the original on 3 April 2007.

More FAQ

^ "FDA approves Cialis to treat benign prostatic hyperplasia". Archived from the original on 18 January 2017. ^ a b Elliott S (10 January 2006). Archived from the original on 22 April 2018. "Viagra and the Battle of the Awkward Ads". The transaction is expected to close in the third quarter of 2025, subject to the satisfaction of customary closing conditions. Grünenthal will finance the transaction using available liquidity. The financial terms of the transaction are not disclosed. Cialis® is indicated for the oral treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in adult men1. The acquisition will expand Grünenthal's Latin American Men's Health la cialis product portfolio.

"Executing on our strategy of targeted acquisitions, Cialis® will expand our existing portfolio in the region and strengthen Grünenthal's Latin American business", says Gabriel Baertschi, CEO, Grünenthal.

7.2 Potential for Other Drugs to Affect CIALIS

Archived from the original on 10 September 2015. Archived from the original (PDF) on 29 August 2021. Archived from the original on 9 November 2021. "Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis". "PD21-09 Daily Tadalafil Therapy: A New Treatment Option for Peyronie's Disease?". "In 2022, we acquired Nebido®, a long-acting treatment for testosterone deficiency, and with Cialis® we can continue to serve our existing customer base and foster our growth in key Latin American markets." Through the acquisition of Cialis®, Grünenthal continues executing its strategy of acquiring established medicines to expand its portfolio and increase its profitability. Since 2017, Grünenthal has invested over €2 billion in the acquisition of established medicines, including Nebido®, the European rights to Crestor® and Nexium®, as well as the global rights to Vimovo® (excluding the U.S. and Japan), Qutenza® and Zomig® (excluding Japan). In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management and, in 2024, acquired the US company Valinor Pharma and the product Movantik®.

• Myths and misconceptions about Cialis are common.
• Myth: It guarantees an erection every time. (Reality: Stimulation needed.)
• Myth: It cures erectile dysfunction. (Reality: It's a treatment, not a cure.)
• Myth: Larger doses work better for everyone. (Reality: Dose is individualized.)
• Myth: It protects against STDs or pregnancy. (Reality: It does not.)
• Myth: It's safe to buy without a prescription online. (Reality: It's risky.)
• Always rely on information from a healthcare professional.

1 In Mexico Cialis® is indicated for the oral treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia in adult men. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx.

• Important contraindications include concurrent use of nitrates (for chest pain).
• Combining with nitrates can cause a dangerous drop in blood pressure.
• It is not recommended for patients with severe heart or liver disease.
• Men with retinitis pigmentosa or certain eye conditions should avoid it.
• Alpha-blockers for BPH or blood pressure require careful dose timing.
• Grapefruit juice may increase tadalafil levels and side effects.
• A thorough cardiovascular assessment is needed before prescribing.

In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion. Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal Click here for our Grünenthal Report 2024/2025 Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia (pdf, 137.3 KB) Singapore, 5 February 2024 Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of two brands, Cialis® (Tadalafil) and Alimta® (Pemetrexed), from Eli Lilly and Company (“Lilly”) for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte. Zanovex will own the trademarks and marketing authorisations, and license manufacturing know-how for Alimta®, an established chemotherapy drug for the treatment of a certain type of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis®, a leading men’s health product for the treatment of erectile dysfunction. ZP Therapeutics, the commercial division of Zuellig Pharma, will promote the two brands in the relevant markets. Prior to the acquisition, ZP Therapeutics was responsible for the promotion and distribution of the brands as part of a broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand.

“This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia,” said John Graham, Group CEO, Zuellig Pharma. Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve.

12.2 Pharmacodynamics

"First they tried to play it safe; Ads for erectile dysfunction drug Cialis bared all - including a scary potential side effect. It was risky but cialis soft gel it has paid off". Archived from the original on 14 December 2019. "Two Pills Look to Topple Viagra's Reign in Market; Levitra Expects Approval Next Month, Cialis Later This Year". Archived from the original on 24 January 2021. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region.

5.14 Consideration of Other Urological Conditions Prior to Initiating Treatment for BPH

"Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US". ^ "Non-Arteritic Anterior Ischemic Optic Neuropathy - Brigham and Women's Hospital". Archived from the original on 28 October 2021. ^ Penedones A, Alves C, Batel Marques F (February 2020). "Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis".

Graduated with Distinction

^ "FDA Announces Revisions to Labels for Cialis, Levitra and Viagra". U.S. Food and Drug Administration (FDA). Archived from the original on 22 October 2016. "Droperidol is predominantly metabolized by human CYP3A enzymes". The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees.

Drug Label Information

"Tadalafil (Cialis) and Vardenafil (Levitra) Recently Approved Drugs for Erectile Dysfunction". Archived from the original on 14 July 2016. "Potency, selectivity, and consequences of nonselectivity cialis 20mg lilly of PDE inhibition". "Deep Pockets + Intense Research + Total Control = The Formula -- Bothell Biotech Icos Keeps The Pipeline Full Of Promise". Archived from the original on 24 February 2012.

What Are the Side Effects of Cialis and Tadalafil?

"2,5-Diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products". "An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals". Archived from the original on 17 October 2014. Archived from the original on 29 April 2015. ^ "FDA approves tadalafil for pulmonary arterial hypertension". Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

• Cialis is FDA-approved for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH).
• For BPH, it helps relax prostate and bladder muscles to improve urine flow.
• It can be prescribed for both conditions simultaneously (ED+BPH).
• The starting dose for daily BPH treatment is typically 5 mg.
• Clinical trials showed significant improvement in BPH symptoms.
• It is not approved for use in women or children.
• Off-label uses exist but are not officially recommended by Lilly.

ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community.

6.2 Postmarketing Experience

Archived from the original on 6 March 2023. Archived from the original on 7 January 2021. Archived from the original on 20 September 2020. ^ British national formulary: BNF 76 (76 ed.). Archived from the original on 30 August 2024.

Looking for more in-depth reviews of these companies?

^ "Tadalafil Drug Usage Statistics, United States, 2013 - 2022". "Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis". "A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction". ^ "Ppsynvi (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)". Archived from the original on 26 November 2021. FDA is alerting consumers and health care professionals that counterfeit versions of Cialis 20 mg tablets were found in the mail on its way to a U.S. consumer. While this shipment was stopped, FDA is concerned about other possible mail shipments to consumers. FDA laboratory analysis showed the counterfeit versions contain multiple active ingredients, which if used could result in adverse effects or harm.